1108 related articles for article (PubMed ID: 26739329)
1. Beta-amyloid deposition and cognitive function in patients with major depressive disorder with different subtypes of mild cognitive impairment: (18)F-florbetapir (AV-45/Amyvid) PET study.
Wu KY; Liu CY; Chen CS; Chen CH; Hsiao IT; Hsieh CJ; Lee CP; Yen TC; Lin KJ
Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1067-76. PubMed ID: 26739329
[TBL] [Abstract][Full Text] [Related]
2. Imaging characteristic of dual-phase (18)F-florbetapir (AV-45/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition in Alzheimer's disease and mild cognitive impairment.
Lin KJ; Hsiao IT; Hsu JL; Huang CC; Huang KL; Hsieh CJ; Wey SP; Yen TC
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1304-14. PubMed ID: 27003417
[TBL] [Abstract][Full Text] [Related]
3. Increased brain amyloid deposition in patients with a lifetime history of major depression: evidenced on 18F-florbetapir (AV-45/Amyvid) positron emission tomography.
Wu KY; Hsiao IT; Chen CS; Chen CH; Hsieh CJ; Wai YY; Chang CJ; Tseng HJ; Yen TC; Liu CY; Lin KJ
Eur J Nucl Med Mol Imaging; 2014 Apr; 41(4):714-22. PubMed ID: 24233127
[TBL] [Abstract][Full Text] [Related]
4. Diversity of neurodegenerative pathophysiology in nondemented patients with major depressive disorder: Evidence of cerebral amyloidosis and hippocampal atrophy.
Wu KY; Lin KJ; Chen CH; Chen CS; Liu CY; Huang SY; Yen TC; Hsiao IT
Brain Behav; 2018 Jul; 8(7):e01016. PubMed ID: 29927088
[TBL] [Abstract][Full Text] [Related]
5. Cortical Amyloid β Deposition and Current Depressive Symptoms in Alzheimer Disease and Mild Cognitive Impairment.
Chung JK; Plitman E; Nakajima S; Chakravarty MM; Caravaggio F; Gerretsen P; Iwata Y; Graff-Guerrero A;
J Geriatr Psychiatry Neurol; 2016 May; 29(3):149-59. PubMed ID: 26400248
[TBL] [Abstract][Full Text] [Related]
6. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
[TBL] [Abstract][Full Text] [Related]
7. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
Tateno A; Sakayori T; Kawashima Y; Higuchi M; Suhara T; Mizumura S; Mintun MA; Skovronsky DM; Honjo K; Ishihara K; Kumita S; Suzuki H; Okubo Y
Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833
[TBL] [Abstract][Full Text] [Related]
8. Beta-amyloid deposition in patients with major depressive disorder with differing levels of treatment resistance: a pilot study.
Li P; Hsiao IT; Liu CY; Chen CH; Huang SY; Yen TC; Wu KY; Lin KJ
EJNMMI Res; 2017 Dec; 7(1):24. PubMed ID: 28324341
[TBL] [Abstract][Full Text] [Related]
9. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease.
Fleisher AS; Chen K; Liu X; Roontiva A; Thiyyagura P; Ayutyanont N; Joshi AD; Clark CM; Mintun MA; Pontecorvo MJ; Doraiswamy PM; Johnson KA; Skovronsky DM; Reiman EM
Arch Neurol; 2011 Nov; 68(11):1404-11. PubMed ID: 21747008
[TBL] [Abstract][Full Text] [Related]
10. Florbetapir Regional Distribution in Cerebral Amyloid Angiopathy and Alzheimer's Disease: A PET Study.
Planton M; Saint-Aubert L; Raposo N; Payoux P; Salabert AS; Albucher JF; Olivot JM; Péran P; Pariente J
J Alzheimers Dis; 2020; 73(4):1607-1614. PubMed ID: 31958082
[TBL] [Abstract][Full Text] [Related]
11. Imaging characteristics and safety of florbetapir (¹⁸F) in Japanese healthy volunteers, patients with mild cognitive impairment and patients with Alzheimer's disease.
Namiki C; Takita Y; Iwata A; Momose T; Senda M; Okubo Y; Joshi AD; Lu M; Agbulos A; Breault C; Pontecorvo MJ
Ann Nucl Med; 2015 Aug; 29(7):570-81. PubMed ID: 25943346
[TBL] [Abstract][Full Text] [Related]
12. Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study.
Doraiswamy PM; Sperling RA; Coleman RE; Johnson KA; Reiman EM; Davis MD; Grundman M; Sabbagh MN; Sadowsky CH; Fleisher AS; Carpenter A; Clark CM; Joshi AD; Mintun MA; Skovronsky DM; Pontecorvo MJ;
Neurology; 2012 Oct; 79(16):1636-44. PubMed ID: 22786606
[TBL] [Abstract][Full Text] [Related]
13. Dual-phase
Kuo HC; Hsiao IT; Hsieh CJ; Huang CY; Huang KL; Wai YY; Chuang WL; Kung MP; Chu YC; Yen TC; Lin KJ; Huang CC
J Formos Med Assoc; 2017 Dec; 116(12):964-972. PubMed ID: 28434708
[TBL] [Abstract][Full Text] [Related]
14. Cognition and amyloid load in Alzheimer disease imaged with florbetapir F 18(AV-45) positron emission tomography.
Rosenberg PB; Wong DF; Edell SL; Ross JS; Joshi AD; Brašić JR; Zhou Y; Raymont V; Kumar A; Ravert HT; Dannals RF; Pontecorvo MJ; Skovronsky DM; Lyketsos CG
Am J Geriatr Psychiatry; 2013 Mar; 21(3):272-8. PubMed ID: 23395194
[TBL] [Abstract][Full Text] [Related]
15. Association between tau deposition and antecedent amyloid-β accumulation rates in normal and early symptomatic individuals.
Tosun D; Landau S; Aisen PS; Petersen RC; Mintun M; Jagust W; Weiner MW;
Brain; 2017 May; 140(5):1499-1512. PubMed ID: 28334939
[TBL] [Abstract][Full Text] [Related]
16. Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and
Ottoy J; Niemantsverdriet E; Verhaeghe J; De Roeck E; Struyfs H; Somers C; Wyffels L; Ceyssens S; Van Mossevelde S; Van den Bossche T; Van Broeckhoven C; Ribbens A; Bjerke M; Stroobants S; Engelborghs S; Staelens S
Neuroimage Clin; 2019; 22():101771. PubMed ID: 30927601
[TBL] [Abstract][Full Text] [Related]
17. Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment.
Camus V; Payoux P; Barré L; Desgranges B; Voisin T; Tauber C; La Joie R; Tafani M; Hommet C; Chételat G; Mondon K; de La Sayette V; Cottier JP; Beaufils E; Ribeiro MJ; Gissot V; Vierron E; Vercouillie J; Vellas B; Eustache F; Guilloteau D
Eur J Nucl Med Mol Imaging; 2012 Apr; 39(4):621-31. PubMed ID: 22252372
[TBL] [Abstract][Full Text] [Related]
18. Independent and Interactive Influences of the APOE Genotype and Beta-Amyloid Burden on Cognitive Function in Mild Cognitive Impairment.
Seo EH; Kim SH; Park SH; Kang SH; Choo IH;
J Korean Med Sci; 2016 Feb; 31(2):286-95. PubMed ID: 26839485
[TBL] [Abstract][Full Text] [Related]
19. 18F-FDG Is a Superior Indicator of Cognitive Performance Compared to 18F-Florbetapir in Alzheimer's Disease and Mild Cognitive Impairment Evaluation: A Global Quantitative Analysis.
Khosravi M; Peter J; Wintering NA; Serruya M; Shamchi SP; Werner TJ; Alavi A; Newberg AB
J Alzheimers Dis; 2019; 70(4):1197-1207. PubMed ID: 31322568
[TBL] [Abstract][Full Text] [Related]
20. 18F PET with florbetapir for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
Martínez G; Vernooij RW; Fuentes Padilla P; Zamora J; Bonfill Cosp X; Flicker L
Cochrane Database Syst Rev; 2017 Nov; 11(11):CD012216. PubMed ID: 29164603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
